| Abstract: | To obtain tumor-selective, photosensitizing drugs useful in the localization of neoplastic tissue and treatment of abnormal neoplastic tissue such as tumors, one of two methods is used. In the first method, a hydrolyzed mixture of the products of reaction of hematoporphyrin with acetic acid and sulfuric acid is cycled through a microporous membrane system to exclude low molecular weight products. In the second method, drugs are synthesized or derived from other pyrrole compounds. The drugs: (1) include two covalently bound groups, each with four rings, some of which are pyrroles such as phlorins, porphyrins, chlorins, substituted pyrroles, substituted chlorins or substituted phlorins, each group being arranged in a ring structure, connected covalently to another group and have a triplet energy state above 37.5 kilocalories per mole; (2) are soluble in water, forming an aggregate of over 10,000 molecular weight in water and have an affinity for each other compared to serum protein such that 10 to 100 percent remain self aggregated in serum protein; and (3) are lipophillic and able to disaggregate and attach to cell plasma, nuclear membrane, mitochondria, lysosomes and tissue. The drug obtained by the first method has an empirical formula of approximately C68H70N8O11 or C68H66N8O11Na4. Neoplastic tissue retains the drug after it has cleared normal tissues and illumination results in necrosis. Moreover, other photosensitizing materials may be combined with a carrier that enters undesirable tissues and cells of the reticular endothelial system such as macrophages. These photosensitizing materials: (1) must have a triplet energy state above 3.5 kilocalories per mole; (2) cannot be easily oxidized; and (3) not physically quench any required energy state. Preferably, this photosensitizing material should be lipophilic. |
|
Patent landscape, scope, and claims: |
United States Patent 4,932,934: Scope, Claim-Construction Levers, and US Landscape
United States Patent 4,932,934 claims a photodynamic therapy (PDT) process that uses a specific porphyrin-aggregate composition derived from hematoporphyrin hydrochloride via acid treatment, controlled pH elevation to generate aggregates of at least 10 kDa, and separation of those aggregates from the balance of the derivative preparation, followed by in vivo tumor illumination with defined dosing, timing, and light delivery parameters.
What is claimed, at the process level?
Claim 1 is the core independent claim (multi-step composition + multi-step treatment)
Claim 1 requires, in a single process, both (i) a defined preparation pathway for the injected photosensitizer composition and (ii) a defined PDT sequence in vivo:
A. Injected composition is porphyrin aggregates with specific functional properties
- “porphyrin aggregates which are fluorescent, photosensitizing and capable of localizing in and being retained in tumor cells for a longer time than in normal tissues”
- The composition is prepared by:
- Starting material: “hematoporphyrin hydrochloride”
- Acid mixture treatment: “treated … with a mixture of acetic acid and sulfuric acid”
- Waiting period: “waiting for a predetermined period of time”
- Illumination reference in claim 1: “illuminating the tumor tissue with light at a predetermined intensity” (this is part of the overall claim process and is not itself a sensitizer-prep step)
- Aggregate creation by pH elevation:
- “raising the pH of a hematoporphyrin derivative preparation in aqueous medium to 6.5-2” (claim language is used as written)
- “to obtain said porphyrin aggregates of 10 kd or greater”
- Aggregate separation:
- “separating said aggregates from the remainder of the hematoporphyrin derivative preparation to obtain said composition”
B. In vivo destruction of tumors by PDT
- “injecting into said host a composition comprising porphyrin aggregates…”
- Then “illuminating the tumor tissue with light at a predetermined intensity”
C. The claim binds both composition manufacture and in vivo use
For infringement, the accused activity must fall within both the required manufacturing features (acid treatment, pH elevation range, aggregate size threshold, separation) and the required PDT performance sequence (tumor illumination after injection).
Which claim elements most narrow scope?
Claim 1 contains several “hard” technical constraints that typically drive claim scope and design-around strategies. The strongest narrowing features are:
1) The aggregate size threshold
- “porphyrin aggregates of 10 kd or greater”
This is an objective structural/size limitation tied to the pH-raising and aggregation/separation method.
2) The pH elevation range used to generate aggregates
- “raising the pH … to 6.5-2” (as written)
This is a numeric range limitation that can be used to distinguish sensitizers prepared with different pH targets, even if they still form aggregates.
3) The acid treatment recipe and dwell time before aggregation
- “treated … with a mixture of acetic acid and sulfuric acid”
- “waiting for a predetermined period of time”
This ties the precursor chemistry to the aggregate characteristics that follow.
4) Separation of aggregates from the remainder
- “separating said aggregates from the remainder …”
- Dependent claim 10 specifies filtration (see below).
5) Tumor-cell retention relative to normal tissue (functional limitation)
- “localizing in and being retained in tumor cells for a longer time than in normal tissues”
This can create scope questions around evidence of retention time superiority and how courts evaluate functional language. Still, it operates as a limitation that is built into Claim 1.
What do the dependent claims add?
Below, dependent claims narrow by specifying dosing, timing, illumination parameters, and light-delivery mechanics.
| Claim |
Added limitation |
Scope effect |
| 2 |
Dosage: “about 1 to 4 mg/kg” |
Narrows administration amounts |
| 3 |
Injection-to-illumination delay: “3 hours to 7 days” |
Narrows treatment schedule |
| 4 |
Illumination intensity: “at least 5 mw/cm2” |
Narrows light power density |
| 5 |
Light delivery: “transmitting radiation through a light conductor… through a diffuser onto the tumor” |
Narrows hardware pathway |
| 6 |
Bidirectional transmission: “transmitting radiation from the tumor back to the source… control the dosage” |
Adds dosimetry feedback architecture |
| 7 |
Diffuser includes “air fill bulb whereby heat is dissipated” |
Narrows thermal management design |
| 8 |
Intensity: “between 0.5 w/cm2 and I kw/cm2” with “thermal effects are obtained.” |
Adds thermal effects rationale and another numeric range (note unit/lettering inconsistency in claim text) |
| 9 |
Aggregate-forming pH is “about 9.5” |
Narrows pH target within Claim 1’s broader range |
| 10 |
Separation effected by “filtering” |
Narrows separation technique |
| 11 |
Maintain “pH of 9.5 during filtration” |
Narrows process control condition |
Key redundancy and interplay
- Claims 9, 10, 11 strongly tighten the composition manufacturing pathway by pinning down pH during a specific unit operation (filtration).
- Claims 5 to 7 narrow light delivery and control scheme, increasing the chances that a different delivery architecture sits outside coverage even if the composition and general PDT are similar.
- Claims 4 and 8 create overlapping but not identical illumination intensity constraints. Both may be relevant depending on claim construction of units and the intended meaning of “mw/cm2” versus “w/cm2” and “I kw/cm2” (as written).
How broad is the process scope relative to PDT generally?
Within US practice, Claim 1 is broad on the PDT concept (tumor photodestruction via photosensitizer injection + illumination), but narrow on the photosensitizer preparation and aggregate characteristics. The claim does not limit:
- tumor type,
- administration route beyond “injecting,”
- specific wavelength of light, except through “predetermined intensity” and dependent hardware features.
However, because Claim 1 explicitly ties the sensitizer to:
- hematoporphyrin hydrochloride conversion via acetic/sulfuric acid treatment,
- controlled pH elevation to form aggregates at/above 10 kDa,
- separation of aggregates,
the real breadth is constrained by whether an accused sensitizer matches that manufacturing and aggregate profile.
What are the strongest infringement hooks?
Direct infringement aligns when all Claim 1 elements are satisfied
For an accused US process to capture Claim 1, it must satisfy, in a single practice:
- Sensitizer is prepared from hematoporphyrin hydrochloride using acetic acid + sulfuric acid mixture with a dwell period.
- The derivative is raised in aqueous medium to the specified pH range “6.5-2” (as written).
- The preparation yields porphyrin aggregates of 10 kDa or greater.
- Those aggregates are separated from the remainder.
- The host is injected with that aggregate composition.
- Tumor tissue is illuminated at a predetermined intensity.
- The composition localizes and retains longer in tumor than normal tissue.
Secondary hooks via dependent claims
- A platform using the same sensitizer but using:
- 1 to 4 mg/kg,
- 3 hours to 7 days delay,
- intensity thresholds,
- diffuser with an air fill bulb,
- filtration at maintained pH 9.5,
would track Claim 2, 3, 4, 7, 11, etc.
Where are the design-around paths most likely to work?
The claims are vulnerable at predictable pressure points:
-
Use a different sensitizer preparation pathway that does not create ≥10 kDa porphyrin aggregates
- If aggregate size distribution stays below 10 kDa (or is not characterized as such), the 10 kDa limitation breaks Claim 1.
-
Use the same general hematoporphyrin chemistry but alter pH targets
- If the process does not raise pH into the “6.5-2” range (as written) and does not produce the required aggregate population, Claim 1 narrows.
-
Avoid the required acid mixture and/or dwell step
- A different precursor preparation recipe (different acid system or no dwell period as required) can avoid the specific “treated … with a mixture of acetic acid and sulfuric acid” limitation.
-
Avoid aggregate separation as claimed
- If you do not “separate said aggregates from the remainder” (and instead administer the unseparated mixture), you fall outside Claim 1.
-
Change light-delivery architecture
- Even if the sensitizer matches, changing to a delivery system that does not use a light conductor plus diffuser, or eliminating bidirectional transmission for dosimetry control, can avoid Claims 5 and 6.
- A different thermal management design can avoid Claim 7.
-
Use substantially different dosing, timing, or intensity
- Claims 2, 3, 4, and 8 are numeric and thus are easy to route around with a different operational window.
Patent landscape in the US: how 4,932,934 tends to sit
How it fits within common US PDT portfolios
The claim set sits inside a well-developed PDT IP space where patents and applications commonly cover:
- photosensitizer chemistry derived from hematoporphyrin fractions,
- aggregation/solubilization control,
- dosing and time-to-illumination windows,
- light delivery using fibers and diffusers,
- feedback-based dosimetry.
This patent’s differentiator is the combination of a defined hematoporphyrin-derived aggregation recipe (acid treatment + specific pH elevation + ≥10 kDa aggregates + separation) with a PDT workflow and, in dependents, specific optical delivery and thermal management.
How that affects freedom-to-operate (FTO)
- If an FTO analysis is centered on PDT generally, 4,932,934 is less likely to be the only barrier because other US patents often exist on:
- hematoporphyrin-derived photosensitizers,
- PDT dosing and timing,
- fiber/diffuser delivery,
- dosimetry control.
- If the sensitizer is the main differentiator, then the assembly of limitations in Claim 1 means fewer competitors will match all preparation and size/separation features simultaneously.
Practical read for developers/investors: the most likely competitors to be captured are those making porphyrin aggregates from hematoporphyrin hydrochloride using acid treatment and controlled pH aggregation with subsequent separation, then using that material for tumor PDT.
Claim-scope risk map by competitor activity type
| Competitor activity |
Risk to 4,932,934 |
Primary reason |
| Same sensitizer chemistry but different light delivery |
Medium to low |
Dependent claims 5 to 7 are delivery-specific |
| Same light delivery and PDT timing but different sensitizer preparation |
Low to medium |
Claim 1’s aggregation prep constraints are hard filters |
| Same sensitizer and PDT operation but different dosage or delay window |
Medium |
Claims 2 and 3 are numeric windows |
| Same sensitizer and PDT sequence with similar intensity |
Medium |
Claims 4 and 8 are intensity thresholds |
| Sensitizer administered without aggregate separation |
Low |
Claim 1 requires aggregate separation |
| Sensitizer has <10 kDa aggregate fraction |
Low |
Claim 1 requires ≥10 kDa aggregates |
Key Takeaways
- Claim 1 is a combined composition-and-use claim: it ties PDT tumor illumination to a hematoporphyrin-derived sensitizer that is made via acetic acid/sulfuric acid treatment, pH elevation to “6.5-2” (as written) to form ≥10 kDa porphyrin aggregates, then separation of those aggregates.
- Dependent claims narrow “how you run it” through dosage (1 to 4 mg/kg), delay (3 hours to 7 days), and light intensity and delivery mechanics (fiber to diffuser, optional bidirectional feedback for dosimetry, diffuser with air fill bulb).
- The main design-around lever is sensitizer manufacture, not illumination wavelength or broad PDT concept. Changing pH/aggregation to avoid the ≥10 kDa aggregate threshold or avoiding required acid treatment/separation most effectively reduces Claim 1 risk.
FAQs
-
Is 4,932,934 limited to a specific light wavelength?
No. The claims emphasize light intensity and delivery hardware, not a wavelength.
-
What is the single most important chemical limitation in Claim 1?
The production of porphyrin aggregates of 10 kDa or greater via the specified pH elevation and separation workflow.
-
Can a competitor infringe Claim 1 using a different photosensitizer, even if it localizes in tumors?
Not under Claim 1 as written. The composition must be prepared by the defined hematoporphyrin hydrochloride acid treatment, pH elevation, and aggregate separation steps.
-
Do Claims 5 to 7 require specific optical hardware?
Yes. Claim 5 requires a light conductor to a diffuser. Claim 6 adds bidirectional transmission for dosage control, and Claim 7 narrows the diffuser to an air fill bulb heat dissipation structure.
-
What operational parameters are numerically constrained?
Dosage (about 1 to 4 mg/kg), delay (about 3 hours to 7 days), and illumination intensity (including “at least 5 mw/cm2” and a separate “0.5 w/cm2 to I kw/cm2” range).
References
[1] United States Patent 4,932,934.
More… ↓
⤷ Start Trial
|
